Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40215432.
- Also identified by DOI 10.1200/JCO-25-00205 and PMC identifier 12084127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the article that accompanies this editorial, Gallois et al. investigate the added value of transcriptomic signatures incorporating tumoral, stromal and immune features to refine the prognosis assessment of stage III colon cancer after resection. If prospectively validated, these findings pave the way for a personalized adjuvant strategy and possibly omission of adjuvant treatment for patients with very low risk disease or therapeutic intensification for high risk disease.